Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
about
Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleedingPlasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot modelA bi-functional anti-thrombosis protein containing both direct-acting fibrin(ogen)olytic and plasminogen-activating activitiesPlasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activatorThrombolysis with plasmin: implications for stroke treatmentComparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary EmbolismCytoprotective protein C pathways and implications for stroke and neurological disordersMiddle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis.Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysisDirect fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential.Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin.Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic strokeFibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.Elevated Factor VIII and von Willebrand Factor Levels Predict Unfavorable Outcome in Stroke Patients Treated with Intravenous Thrombolysis.Practice Trends of Fibrinogen Monitoring in Thrombolysis.
P2860
Q28166487-C1CD6F3D-2177-4BF9-BBC2-AB0E56336B62Q30392562-14EBEF69-2EF0-4011-9EA7-7EA1FDD3B1FCQ30441062-84919F0B-DF83-4724-919B-DC38FC59BD36Q30454936-8F6C1CEA-0F5A-4711-B21E-F86F7A4C0E31Q33851596-AFCDAE71-BC75-4277-B819-0D3E97E28019Q34018715-FA60B0AA-9FD3-420C-B4E7-817CA6A880D5Q35534575-F5F92576-4A52-4986-9550-AF9C6D429F06Q35540504-1D3AD1F6-9059-482B-A617-1285AFB4C411Q35555017-EF2E92E9-FB3C-44DC-AB35-0FC5A10D9E85Q35920702-41F8C31F-C842-4471-BA3A-BC3E442500F0Q36379329-5AD38375-0919-4E81-A4EE-4540D586A810Q36744915-B6AEF196-9E6A-4B66-BA49-A84CD8A1FF5EQ36949037-C4EAD353-4DEB-42B3-9420-83298A03BB3AQ37640163-CC6A04C0-A202-4AF4-A633-3C21E7C337BEQ37903963-574BB4C9-16DA-4296-B44C-8FEB2601D33EQ42271721-0DA593EA-27DB-4E01-BC71-B1CFAEA99659Q44176213-56AABB17-AA8D-4F4A-BBB7-02CB3ECAD2F7Q50147547-B4B38F58-6E2F-4FC1-B343-C34B2B2A5156Q55006343-08F492B4-1816-4356-BA22-AF2D207C6AD6
P2860
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@en
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@nl
type
label
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@en
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@nl
prefLabel
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@en
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@nl
P2093
P1433
P1476
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
@en
P2093
Daphne Stewart
Gary Jesmok
Mansze Kong
Valery Novokhatny
Victor J Marder
P304
P356
10.1182/BLOOD-2002-08-2546
P407
P577
2002-11-21T00:00:00Z